Ultragenyx Pharmaceutical (RARE) Research & Development (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Research & Development data on file, last reported at $187.0 million in Q1 2026.

• On a quarterly basis, Research & Development rose 12.65% year-over-year to $187.0 million in Q1 2026; TTM through Mar 2026 was $771.2 million, a 12.5% increase from a year earlier, with the FY2025 full-year figure at $750.0 million, up 7.45% from the prior year.
• Research & Development for Q1 2026 stood at $187.0 million, down from $203.3 million in the prior quarter.
• Over the last five years, Research & Development for RARE reached as high as $237.3 million in Q3 2022 and fell as low as $143.2 million in Q1 2022.
• Historically, Research & Development has averaged $175.8 million across 5 years, with a median of $166.0 million in 2025.
• Across the five-year window, Research & Development jumped 109.23% in 2022 and slumped 33.73% in 2023, its largest moves.
• Year by year, Research & Development stood at $170.8 million in 2022, then fell by 6.26% to $160.1 million in 2023, then gained by 17.36% to $187.9 million in 2024, then advanced by 8.18% to $203.3 million in 2025, then decreased by 8.01% to $187.0 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $187.0 million in Q1 2026, $203.3 million in Q4 2025, and $216.2 million in Q3 2025.